Kura Oncology (KURA) and Kyowa Kirin announced topline results from KOMET-001, the Phase 2 registration-directed trial of ziftomenib, a highly ...

Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the ...

Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.

Wedbush analyst Robert Driscoll raised the firm’s price target on Kura Oncology (KURA) to $36 from $34 and keeps an Outperform rating on the ...

Kura Oncology and Japan’s Kyowa Kirin have announced that their menin inhibitor ziftomenib met the primary endpoint in a ...

Kura Oncology (KURA) stock slid 7% in post-market trading after the company issued an update on its drug ziftomenib.

He’s been on the road since the ’90s with Chris Cornell, Don Henley, Melissa Etheridge and many others – now the session pro ...

BTIG analyst Justin Zelin downgraded Kura Oncology stock (NASDAQ:KURA) from Buy to Neutral. Zelin cited concerns over the recent KOMET-001 study results for the company's drug, ziftomenib. The ...

H.C. Wainwright maintained a Buy rating on Kura Oncology (NASDAQ:KURA) and raised the price target to $40.00 from the previous $37.00. Trading at $9.05, the stock has seen a strong 12.7% gain over the ...

The acclaimed artist and poet Gürkan Coşkun, who goes by the name Komet, has lived and worked in İstanbul and Paris since the ’70s.

Melanoma is the most aggressive form of skin cancer and often spreads to the brain. Though immunotherapy has greatly improved ...